M&A - TNF Pharmaceuticals, Inc.

Form Type: 10-K

Filing Date: 2025-04-11

Corporate Action: Merger

Type: Update

Accession Number: 000164117225003814

Filing Summary: TNF Pharmaceuticals, Inc. filed its annual report for the fiscal year ended December 31, 2024. The report highlights the company's recent merger with a wholly owned subsidiary, MyMD Pharmaceuticals, Inc., and the subsequent reincorporation in Delaware effective March 4, 2024. The trademark and trading symbol changes were noted, with the company now trading under 'TNFA' after ceasing to trade under 'MYMD'. The document contains details such as the number of shares outstanding as of April 4, 2025, and provides assertions about compliance with SEC filing requirements. Additionally, it discusses the company’s operational status and performance metrics, reflecting on past fiscal performances and outlining expectations moving forward. This 10-K filing entails necessary disclosures and management's assessment of internal controls in adherence to financial reporting standards.

Document Link: View Document